Bevacizumab Alone Versus Dose-dense Temozolomide Followed by Bevacizumab for Recurrent Glioblastoma, Phase III

Nagoya University Hospital, Nagoya

Fujita Health University Hospital, Toyoake

Hirosaki University School of Medicine, Hirosaki

Ehime University Graduate School of Medicine, Shizukawa

Kurume University Hospital, Kurume-shi

Sapporo Medical University Hospital, Sapporo

Kobe University Hospital, Kobe

University of Tsukuba Hospital, Tsukuba

Iwate Medical University, Morioka

Tohoku University Graduate School of Medicine, Sendai

Nagasaki University Hospital, Nagasaki

Kansai Medical University, Hirakata

Osaka University Graduate School of Medicine, Suita

Saga University Hospital, Saga

Saitama Medical University International Medical Center, Hidaka

Dokkyo Medical University, Shimotsuge

Tokyo Medical And Dental University, Medical Hospital, Bunkyō-Ku

University of Yamanashi, Chuo-shi

Chiba University Hospital, Chiba

Kusyu University Graduate School of Medical Sciences, Fukuoka

Hiroshima University Hospital, Hiroshima

Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima

Kitasato University School of Medicine, Kanagawa

Kumamoto University Hospital, Kumamoto

Kyoto University Graduate School of Medicine, Kyoto

Niigata University Medical & Dental Hospital, Niigata

Okayama University Hospital, Okayama

Osaka International Cancer Institute, Osaka

Nakamura Memorial Hospital, Sapporo

Hokkaido University Graduate School of Medicine, Sapporo

Shizuoka Canser Center Hospital, Shizuoka

National Cancer Center Hospital, Tokyo

The University of Tokyo Hospital, Tokyo

Keio University Hospital, Tokyo

Nihon University School of Medicine Itabashi Hospital, Tokyo

Kyorin University Faculty of Medicine, Department of Neurosurgery, Tokyo

Yamagata University Hospital, Yamagata